-
No.1 Scheffler fires sizzling 61 to seize PGA St. Jude lead
-
Arteta tells Arsenal fans not to fret over his future
-
Venezuela frees more political prisoners amid post-Maduro talks
-
Mexico's Indigenous chief justice hits back at discrimination
-
Werro upstages Hodgkinson to win thrilling Euro 800m gold
-
Werro wins 800m race for the ages, Warholm and Tamberi hit four
-
Werro upstages Hodgkinson to win Euro 800m gold
-
Jimenez rescues dramatic Wolves draw in Championship opener
-
Hurricane poised to hit Hawaii as El Nino stirs Pacific
-
Taliban govt to mark five years ruling Afghanistan
-
Ex-Cambridge professor at centre of plagiarism scandal found dead
-
Stocks slip in cautious trading after weak US retail sales data
-
Wildfire threatens Canada wine region
-
Gramercy Networks Announces New Global Ultra-Low Latency Financial Network Connecting Major Trading Hubs
-
'Normal guy' turned killer over US insurance industry grievances
-
NFL bans Falcons defender Pearce eight games for domestic violence
-
Norway's hurdles king Warholm wins fourth European title
-
US says 19 million recalled eggs pose deadly risk
-
Liverpool deal with Bezos consortium raises stakes in US battle for Premier League power
-
Former Cincinnati contenders suffer contrasting first-round fates
-
Colombia hopes for miracles as search for quake victims goes on
-
Argentina's Romero confirms Tottenham exit as Atletico move looms
-
Popovici, Quadarella mine more gold at Europeans as Marchand flexes in butterfly
-
Homeless, jobless: Colombia quake survivors 'left with nothing'
-
'I shot Mr Thompson': Stunning confession in US health exec's slaying
-
Cubans find rest on rooftops as blackouts drive them from home
-
San Francisco to host 2028 MLB All-Star Game
-
World champ McIntosh crashes out of Pan Pacs 400m free
-
Trump dismisses concerns over conditions on US aircraft carrier
-
T'Wolves set Garnett celebration for Celtics clash
-
Zambia resumes vote count after pause over violence
-
Popovici nails freestyle double with third men's European 200m gold
-
Wind spurs forest fire in western Germany, with scores evacuated
-
Premier League club Liverpool sell minority stake to Jeff Bezos consortium
-
Pakistan captain Babar in injury scare ahead of England opener
-
Italian police recover stolen Renoir, Cezanne and Matisse works
-
Mangione admits shooting health care CEO
-
Stocks slip in cautious trading, oil turns higher
-
UN warns sanctions chill is stopping Cuba aid
-
Colombia quake survivor faces life without triplet sisters
-
Alleged US healthcare CEO killer says will plead guilty to stalking
-
Bones of medieval kings saved from Spanish wildfire
-
France's Macron in hot water over jet ski picture
-
US retail sales weakest in over a year, consumer sentiment plunges
-
Nursing federation demands proper pay, protection on Ebola front line
-
In wildfire town, PM says UK must 'face up to climate change'
-
France upholds assisted dying law, strikes down social media ban for children
-
In town hit by wildfire, PM says UK must 'face up to climate change'
-
Body found after wildfire hits Croatian coastal town
-
UK parliament probe into Farage resumes after polls win
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
G.AbuHamad--SF-PST